In the latest step to combat the epidemic of opioid abuse, U.S. officials urge generic drug makers to make changes to opioids.
Mainly supportive of guidelines, but concerns include a lack of evidence underlying some new recommendations.
A pharmacist-led comprehensive medication assessment showed a high prevalence of polypharmacy and inappropriate medication use among older patients with cancer.
Children in remission from acute lymphocytic leukemia (ALL) must take 6-mercaptopurine (6MP) for 2 years to prevent disease reemergence; however, a study shows that an estimated 25% of children in remission are not taking this essential maintenance medication at least 90% of the time, tripling their relapse risk.
Prescribers of extended-release/long-acting opioid analgesics are encouraged to participate in continuing medical education provided by manufacturers of these analgesics.
Falsified and substandard medications pose public health problems around the world, and international action should be taken to combat the phenomenon.
To assist industry in developing new formulations of opioid drugs with abuse-deterrent properties.
One-third of outpatients with breast, prostate, colon/rectum, or lung cancer were receiving insufficient pain treatment, particularly minorities.
Nurses working in hospitals with basic electronic health records report fewer problems with patient safety and quality-related outcomes.
A survey completed by approximately 400 oncology nurses practicing in ambulatory settings indicated that 16.9% had had their skin or eyes exposed to the toxic drugs they deliver.
Palliative care interventions should be introduced at diagnosis as a part of disease management rather than not until the end of life, suggests a review of cancer pain management.
A method employing fluorescent detection appears to be more adept than conventional immunohistochemistry in identifying estrogen receptor (ER)-positive breast cancers.
Disruptions in supply impact patient care. Nurses should know when to use a substitution drug and when to wait for the next shipment.
Roxane Laboratories has made labeling and product-packaging changes to its morphine sulfate oral solution 100 mg per 5 mL (20 mg/mL) due to accidental overdoses that resulted in adverse events and deaths.
A tablet delivering transmucosal fentanyl, Abstral is indicated for the management of breakthrough pain in adult cancer patients who are already using opioids around the clock.
The advisor forum answers questions about drug screens, coping with chemo brain, anemia in patients with MDS, and more.
This article reviews current practices of opioid prescribing in palliative care and suggests some pointers for safe prescribing for these patients.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|